Annual Reports

  • 10-K (Feb 28, 2014)
  • 10-K (Mar 1, 2013)
  • 10-K (Feb 28, 2013)
  • 10-K (Feb 28, 2012)
  • 10-K (Feb 28, 2011)
  • 10-K (Feb 26, 2010)

 
Quarterly Reports

 
8-K

 
Other

Pfizer 10-K 2007

Exhibit 12

PFIZER INC AND SUBSIDIARY COMPANIES
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES

 
Year Ended December 31,
(in millions, except ratios)  
2006
 
 
 
2005
 
 
 
2004
 
 
 
2003
 
 
 
2002
 
Determination of Earnings:                                                      
Income from continuing operations before provision for                                      
   taxes on income, minority interests and cumulative                                      
   effect of a change in accounting principles
$
13,028    
$
10,800     $ 13,403     $ 2,781     $ 11,269  
Less:                                      
   Minority interests   12       12       7       1       3  
Income adjusted for minority interests   13,016       10,788       13,396       2,780       11,266  
Add:                                      
   Fixed charges   642       622       505       438       318  
Total earnings as defined
$
13,658    
$
11,410    
$
13,901    
$
3,218    
$
11,584  
Fixed charges:                                      
   Interest expense (a)
$
488    
$
471     $ 347     $ 270     $ 251  
   Preferred stock dividends (b)   14       14       12       10       --  
   Rents (c)   140       137       146       158       67  
          Fixed charges
  642       622       505       438       318  
   Capitalized interest   29       17       12       20       28  
Total fixed charges
$
671    
$
639    
$
517    
$
458    
$
346  
 
Ratio of earnings to fixed charges   20.4       17.9       26.9       7.0       33.5  

All financial information reflects the following as discontinued operations for all periods presented: the Consumer Healthcare business; for 2006, 2005, 2004 and 2003: certain European generics businesses; and for 2004 and 2003: our in-vitro allergy and autoimmune diagnostics testing, and surgical ophthalmics.

All financial information reflects the following as discontinued operations for 2003, 2002, and 2001: our confectionery, shaving and fish-care products businesses, as well as the Estrostep, Loestrin and femhrt women's health product lines for all the years presented.

(a)          

Interest expense includes amortization of debt premium, discount and expenses.

 
(b)

Preferred stock dividends are from our Series A convertible perpetual preferred stock held by an Employee Stock Ownership Plan assumed in connection with our acquisition of Pharmacia.

 
(c)

Rents included in the computation consist of one-third of rental expense which we believe to be a conservative estimate of an interest factor in our leases, which are not material.

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki